Medtronic unveils results from first-in-human study for EV ICD systems
Category: #health  By Saipriya Iyer  Date: 2019-05-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic unveils results from first-in-human study for EV ICD systems

Medtronic plc has reportedly unveiled the results from a test study of its investigational extravascular ICD system, where a lead is positioned outside of the heart and veins to provide anti-tachycardia pacing therapy and lifesaving defibrillations in one system, using a device as big as conventional, transvenous ICDs.
Reportedly, findings from the study were exhibited over a late-breaking session at the 40th Heart Rhythm Session.

Sources claimed that the pilot study, which denotes the first-in-human long-term use of investigational, first-generation system, exhibits that this system could be implanted without any major complications, and can effectively sense, defibrillate, and pace the heart.

Reportedly, the pilot study was conducted on 21 patients across four sites in Australia and New Zealand. Patients were assessed at implant, 2 weeks, 4 to 6 weeks, and 3 months post device’s implantation, and continue to be followed. As per investigators, the defibrillation tests were conducted on 19 patients, at the time of implant. The system effectively terminated induced ventricular arrhythmias in 17 patients, which is steady with previous clinical trials of existing ICDs. Moreover, the pacing capture was accomplished in over 95 percent of study patients. Among which, one individual suffered ventricular tachycardia outside the hospital premises, which was effectively diagnosed and treated through the EV ICD system, cited investigators.

For the record, through EV ICD systems, Medtronic aims to deliver the benefits of conventional, transvenous ICDs comprising anti-tachycardia pacing to tackle arrhythmias; lifesaving defibrillation therapy; post-shock pacing; and provisional back-up, bradycardia pacing to treat unusually slow heart rates. The EV ICD device is fixed in the left mid-axillary area underneath the left armpit, while the lead is positioned below the sternum or breastbone.

The EV ICD system is investigational globally and therefore, not permitted for sale or distribution, reported sources.

Source Credit: https://www.globenewswire.com/news-release/2019/05/11/1822165/0/en/Medtronic-Reveals-Results-of-First-In-Human-Study-for-Investigational-Extravascular-ICD-System.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...

Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
By Saipriya Iyer

Reliance Industries Ltd., an Indian conglomerate, has reportedly raised Rs.7,500 crore (Dollar 1.02 billion) by selling a stake in its retail unit to Silver Lake Partners, a private equity firm.

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
By Saipriya Iyer

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec G...